APM Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 21:45):

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer...

Stats
Tagesvolumen	48 476.00
Durchschnittsvolumen	2.45M
Marktkapitalisierung	20.48M
EPS	$0 ( 2024-04-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.04
ATR14	$0.0240 (0.49%)

Volumen Korrelation

Lang: 0.13 (neutral)

Kurz: 0.75 (moderate)

Signal:(45.743) Neutral

Aptorum Group Ltd Korrelation

10 Am meisten positiv korreliert
TSHA	0.938
CYTO	0.935
NAKD	0.934
TNGX	0.934
AHPI	0.93
TRIT	0.929
SIRI	0.928
IMV	0.924
JAGX	0.923
TENX	0.923

10 Am meisten negativ korreliert
PUCK	-0.948
THCPU	-0.947
OVLY	-0.945
BRACU	-0.942
XM	-0.939
NCAC	-0.935
WFRD	-0.935
INOD	-0.935
TGTX	-0.934
MCAA	-0.933

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Aptorum Group Ltd Korrelation - Währung/Rohstoff

-0.90
( strong negative )

-0.86
( strong negative )

0.00
( neutral )

-0.84
( strong negative )

0.75
( moderate )

0.85
( strong )

Aptorum Group Ltd Finanzdaten

Annual	2022
Umsatz:	$1.30M
Bruttogewinn:	$80 065.00 (6.18 %)
EPS:	$-14.89

FY	2022
Umsatz:	$1.30M
Bruttogewinn:	$80 065.00 (6.18 %)
EPS:	$-14.89

FY	2021
Umsatz:	$1.54M
Bruttogewinn:	$81 854.00 (5.31 %)
EPS:	$-7.94

FY	2020
Umsatz:	$911 509
Bruttogewinn:	$-103 514 (-11.36 %)
EPS:	$2.24

Financial Reports:

No articles found.

Aptorum Group Ltd

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.